Equities

Lumito AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Lumito AB (publ)

Actions
  • Price (SEK)6.46
  • Today's Change-0.16 / -2.42%
  • Shares traded14.30k
  • 1 Year change-94.31%
  • Beta1.1032
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Lumito AB (publ) is a Sweden-based company engaged in the healthcare sector. The Company focuses on the research of technology within the diagnostics for tissue samples. The Company develops an instrument and reagents for digital pathology, including digitized tissue diagnostics where the analysis is remote and supported with computer-based tools.

  • Revenue in SEK (TTM)81.51k
  • Net income in SEK-48.06m
  • Incorporated2010
  • Employees8.00
  • Location
    Lumito AB (publ)Martenstorget 5LUND 223 51SwedenSWE
  • Phone+46 46162070
  • Websitehttps://lumito.se/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PCI Biotech Holding ASA4.40m-19.29m7.57m7.00--0.6442--1.72-0.5502-0.55020.12560.33530.1676--0.896669,714.30-73.44-41.44-92.22-46.61-----438.10-897.91----0.022--125.25-6.4319.19------
Stayble Therapeutics AB0.00-8.42m12.29m2.00--1.45-----0.168-0.1680.000.13140.00----0.00-78.98-78.82-83.99-92.78------------0.0913------47.69------
Fluicell AB2.68m-9.86m12.71m11.00--1.18--4.74-7.18-7.181.957.860.1257-2.793.22268,100.00-46.21-89.03-62.52-133.15428.8786.83-367.74-656.390.6057--0.00---44.31-5.6641.59--33.86--
Respiratorius AB (publ)0.00-6.95m13.71m----0.448-----1.15-1.150.003.870.00-------22.10---22.91----------------------8.10------
Novakand Pharma AB0.00-51.90m16.68m5.00--0.8325-----0.4283-0.42830.000.16530.00----0.00-103.07-54.11-112.87-63.47--70.00---275,694.40----0.00------31.32------
Gabather AB0.00-4.65m17.11m2.00---------0.0384-0.03840.00-0.01110.00----0.00-209.07-67.13---90.59-----------76.57--------17.84------
ATTANA AB4.10m-12.78m20.64m6.00--0.6084--5.03-0.0154-0.01540.00470.01320.1425-0.76111.02656,600.00-44.37-37.91-61.34-48.09161.16189.23-311.34-305.500.6079-3.790.1315---18.77-8.697.33--8.51--
Lumito AB (publ)81.51k-48.06m22.78m8.00--0.1644--279.46-20.16-20.160.025340.270.0008-0.42240.07916,792.50-47.58-24.12-62.09-26.46546.44---58,966.97-138,894.000.2668-22.920.1994-------61.08---30.66--
Aptahem AB0.00-7.43m30.00m----0.244-----0.6711-0.67110.003.770.00-------11.21-30.70-11.57-34.24-----------44.150.00------22.90--88.99--
Guard Therapeutics Intrntnl AB (publ)0.00-118.48m32.27m5.00--0.58-----7.65-7.650.002.760.00----0.00-161.81-71.09-197.78-79.80-----------1,537.690.00------15.23------
Strategic Partners A/S0.00-4.72m33.23m1.00--1.30-----83.43-83.430.00433.010.00----0.00-18.16-66.13-19.52-94.41-----------69.910.00------98.86------
Peptonic Medical AB15.69m-48.98m33.61m3.00--0.481--2.14-0.0068-0.00680.0020.00370.19940.64913.472,242,000.00-62.23-52.80-86.90-72.8467.8554.48-312.10-141.780.2747-26.440.2863---27.5543.57-40.95--11.04--
Data as of Feb 16 2026. Currency figures normalised to Lumito AB (publ)'s reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.